The emerging link between O-GlcNAc and Alzheimer disease

Journal of Biological Chemistry

Volumn 289, Issue 50, 2014, Pages 34472-34481

  Zhu, Yanping ^a   Shan, Xiaoyang ^a   Yuzwa, Scott A ^a,b   Vocadlo, David J ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOPROTEINS; NEURODEGENERATIVE DISEASES;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEINS; NEURODEGENERATION; NUCLEOCYTOPLASMIC PROTEINS;

PROTEINS;

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; TAU PROTEIN; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; AMYLOID BETA PROTEIN; GLUCOSE; N ACETYLGLUCOSAMINE;

ACYLATION; ALZHEIMER DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLYCOSYLATION; HUMAN; INSULIN RESISTANCE; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; ANIMAL; METABOLISM; PATHOLOGY;

ACETYLGLUCOSAMINE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; GLUCOSE; HUMANS; NEURONS; TAU PROTEINS;

EID: 84918575159     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R114.601351     Document Type: Review

References (100)

1. Lo, R. Y., Hubbard, A. E., Shaw, L. M., Trojanowski, J. Q., Petersen, R. C., Aisen, P. S., Weiner, M. W., and Jagust, W. J. (2011) Longitudinal change of biomarkers in cognitive decline. Arch. Neurol. 68, 1257-1266
2. Beckett, L. A., Harvey, D. J., Gamst, A., Donohue, M., Kornak, J., Zhang, H., and Kuo, J. H. (2010) The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 6, 257-264
3. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Jr., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292
4. Ibáñez, V., Pietrini, P., Alexander, G. E., Furey, M. L., Teichberg, D., Rajapakse, J. C., Rapoport, S. I., Schapiro, M. B., and Horwitz, B. (1998) Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 50, 1585-1593
5. 18F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U.S.A. 98, 10966-10971
6. De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., Tsui, W. H., Kandil, E., Boppana, M., Daisley, K., Wang, G. J., Schlyer, D., and Fowler, J. (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 22, 529-539
7. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. (1999) Soluble pool of Aβamyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866
8. Mosconi, L., Pupi, A., and De Leon, M. J. (2008) Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. N.Y. Acad. Sci. 1147, 180-195
9. Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A., Hofman, A., and Breteler, M. M. (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942
10. Peila, R., Rodriguez, B. L., Launer, L. J., and Honolulu-Asia Aging, S. (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262
11. Calvo-Ochoa, E., and Arias, C. (2014) Cellular and metabolic alterations in the hippocampus caused by insulin signaling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease. Animal models of study. Diabetes Metab. Res. Rev. 10.1002/dmrr.2531
12. Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., Oliveira, C. R., and Moreira, P. I. (2012) Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res. 1441, 64-78
13. de la Monte, S. M. (2009) Insulin resistance and Alzheimer's disease. BMB Rep. 42, 475-481
14. Frölich, L., Blum-Degen, D., Bernstein, H. G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., Zöchling, R., Boissl, K. W., Jellinger, K., and Riederer, P. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J. Neural. Transm. 105, 423-438
15. Liu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I., and Gong, C. X. (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 582, 359-364
16. Dodart, J. C., Mathis, C., Bales, K. R., Paul, S. M., and Ungerer, A. (1999) Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F β-amyloid precursor protein. Neurosci. Lett. 277, 49-52
17. Nicholson, R. M., Kusne, Y., Nowak, L. A., LaFerla, F. M., Reiman, E. M., and Valla, J. (2010) Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res. 1347, 179-185
18. Sadowski, M., Pankiewicz, J., Scholtzova, H., Ji, Y., Quartermain, D., Jensen, C. H., Duff, K., Nixon, R. A., Gruen, R. J., and Wisniewski, T. (2004) Amyloid-β deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J. Neuropathol. Exp. Neurol. 63, 418-428
19. 18F]FDG PET study. Neurology 68, 501-508
20. Cohen, A. D., Price, J. C., Weissfeld, L. A., James, J., Rosario, B. L., Bi, W., Nebes, R. D., Saxton, J. A., Snitz, B. E., Aizenstein, H. A., Wolk, D. A., Dekosky, S. T., Mathis, C. A., and Klunk, W. E. (2009) Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve. J. Neurosci. 29, 14770-14778
21. Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., and Craft, S. (2011) Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68, 51-57
22. Burns, C. M., Chen, K., Kaszniak, A. W., Lee, W., Alexander, G. E., Bandy, D., Fleisher, A. S., Caselli, R. J., and Reiman, E. M. (2013) Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology 80, 1557-1564
23. Bitel, C. L., Kasinathan, C., Kaswala, R. H., Klein, W. L., and Frederikse, P. H. (2012) Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J. Alzheimers Dis. 32, 291-305
24. Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Emond, V., Julien, P., and Calon, F. (2010) High-fat diet aggravates amyloid-β and tau pathologies in the 3xTg-AD mouse model. Neurobiol. Aging 31, 1516-1531
25. Ke, Y. D., Delerue, F., Gladbach, A., Götz, J., and Ittner, L. M. (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS ONE 4, e7917
26. Leboucher, A., Laurent, C., Fernandez-Gomez, F. J., Burnouf, S., Troquier, L., Eddarkaoui, S., Demeyer, D., Caillierez, R., Zommer, N., Vallez, E., Bantubungi, K., Breton, C., Pigny, P., Buée-Scherrer, V., Staels, B., Hamdane, M., Tailleux, A., Buée, L., and Blum, D. (2013) Detrimental effects of diet-induced obesity on tau pathology are independent of insulin resistance in tau transgenic mice. Diabetes 62, 1681-1688
27. Zachara, N. E., O'Donnell, N., Cheung, W. D., Mercer, J. J., Marth, J. D., and Hart, G. W. (2004) Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J. Biol. Chem. 279, 30133-30142
28. Torres, C. R., and Hart, G. W. (1984) Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J. Biol. Chem. 259, 3308-3317
29. Vosseller, K., Trinidad, J. C., Chalkley, R. J., Specht, C. G., Thalhammer, A., Lynn, A. J., Snedecor, J. O., Guan, S., Medzihradszky, K. F., Maltby, D. A., Schoepfer, R., and Burlingame, A. L. (2006) O-Linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol. Cell. Proteomics 5, 923-934
30. Trinidad, J. C., Barkan, D. T., Gulledge, B. F., Thalhammer, A., Sali, A., Schoepfer, R., and Burlingame, A. L. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol. Cell. Proteomics 11, 215-229
31. Skorobogatko, Y. V., Deuso, J., Adolf-Bryfogle, J., Nowak, M. G., Gong, Y., Lippa, C. F., and Vosseller, K. (2011) Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry. Amino Acids 40, 765-779
32. Hart, G. W., Housley, M. P., and Slawson, C. (2007) Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446, 1017-1022
33. Vocadlo, D. J. (2012) O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation. Curr. Opin. Chem. Biol. 16, 488-497
34. Kreppel, L. K., Blomberg, M. A., and Hart, G. W. (1997) Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem. 272, 9308-9315
35. Lubas, W. A., Frank, D. W., Krause, M., and Hanover, J. A. (1997) O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J. Biol. Chem. 272, 9316-9324
36. Gao, Y., Wells, L., Comer, F. I., Parker, G. J., and Hart, G. W. (2001) Dynamic O-glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a neutral, cytosolic β-N-acetylglucosaminidase from human brain. J. Biol. Chem. 276, 9838-9845
37. Chou, C. F., Smith, A. J., and Omary, M. B. (1992) Characterization and dynamics of O-linked glycosylation of human cytokeratin 8 and 18. J. Biol. Chem. 267, 3901-3906
38. Roquemore, E. P., Chevrier, M. R., Cotter, R. J., and Hart, G. W. (1996) Dynamic O-GlcNAcylation of the small heat shock protein αB-crystallin. Biochemistry 35, 3578-3586
39. Cheng, X., and Hart, G. W. (2001) Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor β. Post-translational regulation of turnover and transactivation activity. J. Biol. Chem. 276, 10570-10575
40. Chou, T. Y., Hart, G. W., and Dang, C. V. (1995) c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J. Biol. Chem. 270, 18961-18965
41. Smet-Nocca, C., Broncel, M., Wieruszeski, J. M., Tokarski, C., Hanoulle, X., Leroy, A., Landrieu, I., Rolando, C., Lippens, G., and Hackenberger, C. P. (2011) Identification of O-GlcNAc sites within peptides of the tau protein and their impact on phosphorylation. Mol. Biosyst. 7, 1420-1429
42. Dias, W. B., Cheung, W. D., Wang, Z., and Hart, G. W. (2009) Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc modification. J. Biol. Chem. 284, 21327-21337
43. Wang, Z., Gucek, M., and Hart, G. W. (2008) Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc. Natl. Acad. Sci. U.S.A. 105, 13793-13798
44. Tarrant, M. K., Rho, H. S., Xie, Z., Jiang, Y. L., Gross, C., Culhane, J. C., Yan, G., Qian, J., Ichikawa, Y., Matsuoka, T., Zachara, N., Etzkorn, F. A., Hart, G. W., Jeong, J. S., Blackshaw, S., Zhu, H., and Cole, P. A. (2012) Regulation of CK2 by phosphorylation and O-GlcNAcylation revealed by semisynthesis. Nat. Chem. Biol. 8, 262-269
45. Lefebvre, T., Ferreira, S., Dupont-Wallois, L., Bussière, T., Dupire, M. J., Delacourte, A., Michalski, J. C., and Caillet-Boudin, M. L. (2003) Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of tau proteins-a role in nuclear localization. Biochim. Biophys. Acta 1619, 167-176
46. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., and Gong, C. X. (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 10804-10809
47. Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X., Dennis, R. J., He, Y., Whitworth, G. E., Stubbs, K. A., McEachern, E. J., Davies, G. J., and Vocadlo, D. J. (2008) A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 4, 483-490
48. Graham, D. L., Gray, A. J., Joyce, J. A., Yu, D., O'Moore, J., Carlson, G. A., Shearman, M. S., Dellovade, T. L., and Hering, H. (2014) Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Neuropharmacology 79, 307-313
49. Yu, Y., Zhang, L., Li, X., Run, X., Liang, Z., Li, Y., Liu, Y., Lee, M. H., Grundke-Iqbal, I., Iqbal, K., Vocadlo, D. J., Liu, F., and Gong, C. X. (2012) Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS ONE 7, e35277
50. Okuyama, R., and Marshall, S. (2003) UDP-N-acetylglucosaminyltransferase (OGT) in brain tissue: temperature sensitivity and subcellular distribution of cytosolic and nuclear enzyme. J. Neurochem. 86, 1271-1280
51. Rex-Mathes, M., Werner, S., Strutas, D., Griffith, L. S., Viebahn, C., Thelen, K., and Schmitz, B. (2001) O-GlcNAc expression in developing and ageing mouse brain. Biochimie 83, 583-590
52. Liu, Y., Li, X., Yu, Y., Shi, J., Liang, Z., Run, X., Li, Y., Dai, C. L., Grundke-Iqbal, I., Iqbal, K., Liu, F., and Gong, C. X. (2012) Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain. PLoS ONE 7, e43724
53. Akimoto, Y., Comer, F. I., Cole, R. N., Kudo, A., Kawakami, H., Hirano, H., and Hart, G. W. (2003) Localization of the O-GlcNAc transferase and O-GlcNAc-modified proteins in rat cerebellar cortex. Brain Res. 966, 194-205
54. Liu, K., Paterson, A. J., Zhang, F., McAndrew, J., Fukuchi, K., Wyss, J. M., Peng, L., Hu, Y., and Kudlow, J. E. (2004) Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J. Neurochem. 89, 1044-1055
55. Cole, R. N., and Hart, G. W. (2001) Cytosolic O-glycosylation is abundant in nerve terminals. J. Neurochem. 79, 1080-1089
56. Zhang, X., and Bennett, V. (1996) Identification of O-linked N-acetyl-glucosamine modification of ankyrin G isoforms targeted to nodes of Ranvier. J. Biol. Chem. 271, 31391-31398
57. O'Donnell, N., Zachara, N. E., Hart, G. W., and Marth, J. D. (2004) Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol. Cell. Biol. 24, 1680-1690
58. Pekkurnaz, G., Trinidad, J. C., Wang, X., Kong, D., and Schwarz, T. L. (2014) Glucose regulates mitochondrial motility via milton modification by O-GlcNAc transferase. Cell 158, 54-68
59. Li, X., Lu, F., Wang, J. Z., and Gong, C. X. (2006) Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur. J. Neurosci. 23, 2078-2086
60. Marshall, S., Bacote, V., and Traxinger, R. R. (1991) Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 266, 4706-4712
61. Liu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132, 1820-1832
62. Förster, S., Welleford, A. S., Triplett, J. C., Sultana, R., Schmitz, B., and Butterfield, D. A. (2014) Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim. Biophys. Acta 1842, 1333-1339
63. Griffith, L. S., and Schmitz, B. (1995) O-linked N-acetylglucosamine is upregulated in Alzheimer brains. Biochem. Biophys. Res. Commun. 213, 424-431
64. Ksiezak-Reding, H., Liu, W. K., and Yen, S. H. (1992) Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 597, 209-219
65. Cho, J. H., and Johnson, G. V. (2004) Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3β (GSK3β) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J. Neurochem. 88, 349-358
66. Lindwall, G., and Cole, R. D. (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301-5305
67. Sengupta, A., Kabat, J., Novak, M., Wu, Q., Grundke-Iqbal, I., and Iqbal, K. (1998) Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357, 299-309
68. Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. U.S.A. 98, 6923-6928
69. Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., and Wisniewski, H. M. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084-6089
70. Nukina, N., Kosik, K. S., and Selkoe, D. J. (1987) Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc. Natl. Acad. Sci. U.S.A. 84, 3415-3419
71. de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., Spires-Jones, T. L., and Hyman, B. T. (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697
72. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M., and Ashe, K. H. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481
73. Frost, B., Jacks, R. L., and Diamond, M. I. (2009) Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845-12852
74. Kfoury, N., Holmes, B. B., Jiang, H., Holtzman, D. M., and Diamond, M. I. (2012) Trans-cellular propagation of tau aggregation by fibrillar species. J. Biol. Chem. 287, 19440-19451
75. Le Corre, S., Klafki, H. W., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, H., Monse, B., Seneci, P., Lewis, J., Eriksen, J., Zehr, C., Yue, M., McGowan, E., Dickson, D. W., Hutton, M., and Roder, H. M. (2006) An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 103, 9673-9678
76. Uno, Y., Iwashita, H., Tsukamoto, T., Uchiyama, N., Kawamoto, T., Kori, M., and Nakanishi, A. (2009) Efficacy of a novel, orally active GSK-3 inhibitor 6-methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice. Brain Res. 1296, 148-163
77. Arnold, C. S., Johnson, G. V., Cole, R. N., Dong, D. L., Lee, M., and Hart, G. W. (1996) The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J. Biol. Chem. 271, 28741-28744
78. Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., and Vocadlo, D. J. (2012) Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 8, 393-399
79. Yuzwa, S. A., Yadav, A. K., Skorobogatko, Y., Clark, T., Vosseller, K., and Vocadlo, D. J. (2011) Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody. Amino Acids 40, 857-868
80. Wang, Z., Udeshi, N. D., O'Malley, M., Shabanowitz, J., Hunt, D. F., and Hart, G. W. (2010) Enrichment and site mapping of O-linked N-acetyl-glucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry. Mol. Cell. Proteomics 9, 153-160
81. Baker, M., Kwok, J. B., Kucera, S., Crook, R., Farrer, M., Houlden, H., Isaacs, A., Lincoln, S., Onstead, L., Hardy, J., Wittenberg, L., Dodd, P., Webb, S., Hayward, N., Tannenberg, T., Andreadis, A., Hallupp, M., Schofield, P., Dark, F., and Hutton, M. (1997) Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21-22. Ann. Neurol. 42, 794-798
82. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W. L., Yen, S. H., Dickson, D. W., Davies, P., and Hutton, M. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405
83. Terwel, D., Lasrado, R., Snauwaert, J., Vandeweert, E., Van Haesendonck, C., Borghgraef, P., and Van Leuven, F. (2005) Changed conformation of mutant tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of tau-4R/2N transgenic mice. J. Biol. Chem. 280, 3963-3973
84. Yuzwa, S. A., Cheung, A. H., Okon, M., McIntosh, L. P., and Vocadlo, D. J. (2014) O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J. Mol. Biol. 426, 1736-1752
85. Cameron, A., Giacomozzi, B., Joyce, J., Gray, A., Graham, D., Ousson, S., Neny, M., Beher, D., Carlson, G., O'Moore, J., Shearman, M., and Hering, H. (2013) Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400. FEBS Lett. 587, 3722-3728
86. Borghgraef, P., Menuet, C., Theunis, C., Louis, J. V., Devijver, H., Maurin, H., Smet-Nocca, C., Lippens, G., Hilaire, G., Gijsen, H., Moechars, D., and Van Leuven, F. (2013) Increasing brain protein O-GlcNAcylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS ONE 8, e84442
87. Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., Haass, C., and Fahrenholz, F. (1999) Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U.S.A. 96, 3922-3927
88. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741
89. De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., and Van Leuven, F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387-390
90. Estus, S., Golde, T. E., Kunishita, T., Blades, D., Lowery, D., Eisen, M., Usiak, M., Qu, X. M., Tabira, T., and Greenberg, B. D. (1992) Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science 255, 726-728
91. Griffith, L. S., Mathes, M., and Schmitz, B. (1995) β-Amyloid precursor protein is modified with O-linked N-acetylglucosamine. J. Neurosci. Res. 41, 270-278
92. Jacobsen, K. T., and Iverfeldt, K. (2011) O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-β precursor protein (APP). Biochem. Biophys. Res. Commun. 404, 882-886
93. Macauley, M. S., and Vocadlo, D. J. (2010) Increasing O-GlcNAc levels: an overview of small-molecule inhibitors of O-GlcNAcase. Biochim. Biophys. Acta 1800, 107-121
94. Kim, C., Nam, D. W., Park, S. Y., Song, H., Hong, H. S., Boo, J. H., Jung, E. S., Kim, Y., Baek, J. Y., Kim, K. S., Cho, J. W., and Mook-Jung, I. (2013) O-Linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment. Neurobiol. Aging 34, 275-285
95. Yuzwa, S. A., Shan, X., Jones, B. A., Zhao, G., Woodward, M. L., Li, X., Zhu, Y., McEachern, E. J., Silverman, M. A., Watson, N. V., Gong, C. X., Vocadlo, D. J. (2014) Pharmacological Inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. Mol. Neurodegener. 9, 42
96. Francisco, H., Kollins, K., Varghis, N., Vocadlo, D., Vosseller, K., and Gallo, G. (2009) O-GlcNAc post-translational modifications regulate the entry of neurons into an axon branching program. Dev. Neurobiol. 69, 162-173
97. Tallent, M. K., Varghis, N., Skorobogatko, Y., Hernandez-Cuebas, L., Whelan, K., Vocadlo, D. J., and Vosseller, K. (2009) In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J. Biol. Chem. 284, 174-181
98. Wang, P., Lazarus, B. D., Forsythe, M. E., Love, D. C., Krause, M. W., and Hanover, J. A. (2012) O-GlcNAc cycling mutants modulate proteotoxicity in Caenorhabditis elegans models of human neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 109, 17669-17674
99. de la Monte, S. M., and Tong, M. (2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol. 88, 548-559
100. Macauley, M. S., Shan, X., Yuzwa, S. A., Gloster, T. M., and Vocadlo, D. J. (2010) Elevation of global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis. Chem. Biol. 17, 949-958